Methods of inhibiting viral replication using IL-10

• US 5,665,345 A
• Filed: 05/24/1993
• Issued: 09/09/1997
• Est. Priority Date: 05/24/1993
• Status: Expired due to Term

• Current Assignee: United States Department Of Health And Human Services (Government of the United States of America)
• Original Assignee: United States Department Of Health And Human Services (Government of the United States of America)
• Inventors: Saville, M. Wayne, Taga, Kazuyuki, Tosato, Giovanna, Yarchoan, Robert
• Primary Examiner(s): Sayala, Chhaya D.
• Application Number:
  US08/066,785
• Time in Patent Office: 1,569 Days
• Field of Search: 424/85.1, 424/85.2, 424/85.7
• US Class Current: 424/85.2
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/2066 IL-10

Abstract

The present invention provides a method of inhibiting the replication of human immunodeficiency virus in cells which are infected with HIV comprising administering to the cells a replication inhibiting amount of interleukin-10. Also provided is a parenteral method of the administration of interleukin-10 administration. Further provided is a method of inhibiting retroviral replication in a human subject infected by a retrovirus, comprising administering to the subject an inhibiting amount of interleukin-10, including the retrovirus is. Finally, a method of treating Kaposi'"'"'s sarcoma in a human subject comprising administering to the subject an effective amount of interleukin-10 to the subject is provided.

Claims

1. A method of therapeutically inhibiting the replication of human immunodeficiency virus in human cells in or from a human subject comprising administering to the cells a replication inhibiting amount of interleukin-10.

2. The method of claim 1, wherein the cells are in a human subject and the interleukin-10 administration is parenteral.

3. The method of claim 1, wherein the cells are in a human subject and the interleukin-10 administration is sublingual.

4. The method of claim 1, wherein the interleukin-10 is administered to blood cells removed from a subject and returned after treatment.

5. The method of claim 4, wherein the amount of interleukin-10 administered is between about 0.001 and 1 units/ml.

6. The method of claim 4, wherein the amount of interleukin-10 administered is between about 0.01 and 1 units/ml.

7. The method of claim 1, further comprising administering a compound having anti-human immunodeficiency virus activity.

8. The method of claim 7, wherein the compound is selected from the group consisting of zidovudine, zalcitabine, didanosine and stavudine.

9. The method of claim 1, wherein the cells are selected from the group consisting of monocytes, macrophages and monocyte derived cells.

10. A method of treating a disease caused by human immunodeficiency virus in a human subject comprising administering a replication inhibiting amount of interleukin-10 to the subject.

11. The method of claim 10, wherein the interleukin-10 administration is parenteral.

12. The method of claim 10, wherein the administration is sublingual.

13. The method of claim 10, wherein the interleukin-10 is administered to blood removed from the subject and returned after treatment.

14. The method of claim 10, wherein the amount of interleukin-10 administered is between about 1,000 and 1,000,000 units.

15. The method of claim 10, wherein the amount of interleukin-10 administered is between about 20,000 and 200,000 units.

16. The method of claim 10, further comprising administering a compound having anti-human immunodeficiency virus activity.

17. The method of claim 16, wherein the compound is selected from the group consisting of zidovudine, zalcitabine, didanosine and stavudine.

18. The method of claim 10, wherein the disease is acquired immunodeficiency syndrome.

19. The method of claim 10, wherein the disease is human immunodeficiency virus disease.

20. The method of claim 10, wherein the disease is human immunodeficiency virus associated dementia.

21. The method of claim 10, wherein the disease is autoimmune disease.

22. A method of inhibiting retroviral replication in a human subject infected by a retrovirus comprising administering to the subject an inhibiting amount of interleukin-10.

23. The method of claim 22, wherein the interleukin-10 administration is parenteral.

24. The method of claim 22, wherein the interleukin-10 administration is sublingual.

25. The method of claim 22, wherein the amount of interleukin-10 administered is between about 1,000 and 1,000,000 units.

26. The method of claim 22, wherein the mount of interleukin-10 administered is between about 20,000 and 200,000 units.

27. The method of claim 22, wherein the interleukin-10 is administered to blood removed from the subject and returned after treatment.

28. The method of claim 22, further comprising administering a compound having anti-retrovirus activity.

29. The method of claim 28, wherein the compound is selected from the group consisting of zidovudine, zalcitabine, didanosine and stavudine.

30. A method of treating Kaposi'"'"'s sarcoma in a human subject comprising administering to the subject an effective amount of interleukin-10 to the subject.